Chimerix Completes Targeted Enrollment for Brincidofovir

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Chimerix Completes Targeted Enrollment for Brincidofovir Phase 3 SUPPRESS Trial

Topline Data on Cytomegalovirus (CMV) Prevention in Hematopoietic Cell

Transplant Patients Anticipated in Early 2016

DURHAM, N.C., June 8, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX ), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the successful enrollment of the targeted 450 patients in SUPPRESS, the Phase 3 trial evaluating brincidofovir for the prevention of clinically significant cytomegalovirus (CMV) infection in hematopoietic cell transplant (HCT), also known as bone marrow or stem cell transplant recipients. The company anticipates reporting topline data from SUPPRESS in early 2016.

"We have reached our targeted 450 enrolled patients in SUPPRESS, a major milestone for Chimerix that brings us closer to providing potential evidence of brincidofovir's activity against viruses that have such a negative impact on these vulnerable patients," said W. Garrett Nichols, MD, MS, Chief Medical Officer of Chimerix. "The enrollment of this large trial in less than two years speaks to the need for a new antiviral that is active against CMV and other DNA viruses. There has not been a new antiviral approved in this therapeutic area in over a decade."

The lead physician investigator for SUPPRESS, Francisco Marty, MD, of Dana-Farber Cancer Institute in Boston, said, "If approved, brincidofovir will be the first antiviral indicated for the prevention of clinically significant CMV infections in allogeneic bone marrow transplant patients at increased risk of CMV. Although prevention of CMV infections has long been the objective in transplant medicine, available antivirals have not had the safety profile to allow their use in the broader patient population who remain at risk of CMV in the months following a stem cell transplant. We are extremely grateful to all the patients who have taken part in this landmark study."

The primary endpoint of SUPPRESS is prevention of clinically significant CMV infection through the first 24 weeks post-transplant. Important secondary endpoints in the trial include the prevention of clinically relevant infections with other DNA viruses that often coexist in immunocompromised patients, such as adenovirus, Epstein-Barr virus (EBV) and BK virus; the prevention of bacterial and fungal infections that can be associated with CMV reactivation; the potential associated benefits of preventing CMV such as decreased rates of re-hospitalizations and other measures of healthcare utilization; and the potential to decrease overall mortality in the critical first months following the transplant.

The SUPPRESS trial has enrolled 450 adult HCT recipients who are at increased risk for CMV infection from over 40 of the key transplant centers in the U.S., Canada and Europe. Subjects receive twice-weekly brincidofovir or placebo (2:1 ratio) from the early post-transplant period through week 14 post-transplant, the period of highest risk for viral infections.

The company plans to formally review with the U.S. Food and Drug Administration (FDA) a strategy of submitting a new drug application (NDA) for brincidofovir with efficacy and safety data from both the pivotal SUPPRESS and AdVise trials. The Phase 3 AdVise trial for the treatment of life-threatening adenovirus infection began in March 2014 and has enrolled over 150 patients to date. In an analysis presented earlier this year, more than half of the patients enrolled in AdVise had two or more active viral infections, underscoring the significant risks that transplant recipients currently face. If approved, brincidofovir could be the first antiviral with the safety profile to allow use as a prevention of clinically significant CMV infection and potentially other viral infections in these high-risk patients.

About Hematopoietic Cell Transplantation (HCT)

More than 70,000 hematopoietic cell transplants (HCT) are performed each year worldwide, most frequently to treat patients with certain cancers of the blood and bone marrow, or to address genetic diseases. Due to chemotherapy and the immune suppression associated with HCT, patients are highly susceptible to viral, bacterial and fungal infections. These complications are a significant cause of morbidity and mortality in the months following the transplant, and too often the high risk of infection in the first year after transplant results in patients and their families deciding to not undergo a potentially curative transplant.

About Cytomegalovirus (CMV)

Cytomegalovirus (CMV) is a member of the herpesvirus family and remains a significant cause of viral infections in transplant recipients.  A majority of adults in the U.S. have evidence of a prior infection with CMV which establishes a dormant or latent infection that cannot be cleared; most individuals have an immune system that is able to prevent CMV from reactivating and causing disease. In individuals with weakened immune systems – such as transplant recipients – CMV commonly reactivates during the first weeks following the transplant, leading to infection of the lungs or other organ system and increasing the risk of other viral, bacterial and fungal infections. No therapies are approved for the prevention of CMV in HCT recipients because of known toxicities associated with available CMV antivirals, including bone marrow suppression and renal impairment.

About Brincidofovir (CMX001)

Chimerix's lead product candidate, brincidofovir, is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including the herpesvirus family and adenovirus. Brincidofovir has not been associated with kidney or bone marrow toxicity in over 1,000 patients treated to date. Based on the clinically and statistically significant Phase 2 results in cytomegalovirus (CMV) prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix's initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients. Chimerix is also conducting AdVise, a Phase 3 trial in patients with adenovirus infection, which is an often-fatal viral infection with no approved treatment. Chimerix is working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157, which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com .

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that the FDA and other regulatory authorities may not approve brincidofovir or brincidofovir-based regimens in the currently anticipated timelines or at all, and marketing approvals, if granted, may have significant limitations on their use. As a result, brincidofovir may never be successfully commercialized. In addition, Chimerix may be unable to file for regulatory approval for brincidofovir with other regulatory authorities in the currently anticipated timelines. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Chimerix's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Chimerix, and Chimerix assumes no obligation to update any such forward-looking statements.

For further information, please visit Chimerix's website,  www.chimerix.com

Joseph T. Schepers Executive Director, Investor Relations and Corporate Communications 919-287-4125

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 21

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 20

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 226

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 77

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 12

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading

Top 5 Most Recently Viewed Articles

Steel Dynamics Insider Sell: Key Insights and Future Outlook

Updated Category News Views 91

Understanding Recent Insider Transactions at Steel Dynamics In a noteworthy development, James Stanley Anderson, the Senior Vice President of Steel Dynamics (NASDAQ: STLD), executed a substantial sell-off of shares, raising eyebrows among investors and industry analysts alike. This insider transaction, reported through an SEC filing, includes the sale of 10,000 shares,...

Continue Reading
Final Cash Distributions for iShares Premium Money Market ETF

Updated Category News Views 182

Final Cash Distributions Announced BlackRock Asset Management Canada Limited has recently revealed significant cash distributions for the iShares Premium Money Market ETF. This announcement, which is essential for investors looking to optimize their financial strategies, includes details on the cash distributions that will be made available for unitholders. Distribution...

Continue Reading
Sina Corporation Investors Encouraged to Join Class Action

Updated Category News Views 161

Sina Corporation Investors Encouraged to Join Class Action Attention investors of Sina Corporation (NASDAQ:SINA): If you've experienced significant financial losses related to the company's stock, you have a valuable opportunity to take action. A class action lawsuit has been initiated against Sina and its executives. Understanding the Class Action The lawsuit has been...

Continue Reading
Talisker’s Bralorne Gold Project Shows Thriving Ore Sorting Potential

Updated Category News Views 258

Talisker’s Innovative Approach to Ore Sorting Talisker Resources Ltd. is excited to share that promising outcomes have surfaced from its initial testing of ore sorting technologies at the Bralorne Gold Project. This flagship site, situated in British Columbia, is undergoing a revitalization aimed at enhancing gold recovery processes. The success of these technologies...

Continue Reading
Avalanche Experiences Significant Price Surge of 5.53% in One Day

Updated Category News Views 79

Avalanche Sees Impressive Market Performance Avalanche (AVAX) has demonstrated a remarkable surge in the cryptocurrency market, with its price climbing 5.53% in just 24 hours, now sitting at $29.11. This impressive rise is part of a larger trend, as the coin has seen a weekly increase of over 10%, up from $26.40. Notably, the coin has reached an all-time high of $144.96,...

Continue Reading